Medlab Clinical Ltd (ASX: MDC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Medlab Clinical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.07 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.28 million
Earnings per share -547.781
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Medlab Clinical Ltd (ASX: MDC)
    Latest News

    a woman
    ⏸️ Investing

    Here are 2017's best performing ASX pot stocks

    Australia’s pot stocks have been a hot topic this year. And some have proved very lucrative for shareholders.

    Read more »

    a woman
    ⏸️ Investing

    Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients

    The Medlab Clinical Ltd (ASX:MDC) plans to test cannabis at Royal North Shore Hospital. And investors seem to think that’s…

    Read more »

    MDC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Medlab Clinical Ltd

    Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Kenneth Carter Non-Executive Director Mar 2023
    Mr Carter is experienced in structuring corporate transactions and has also worked in ongoing corporate advisory roles with numerous ASX listed entities over the last 18 years. Mr Carter has been employed as a stockbroker since 1999 and was previously a director of Indian Ocean Capital. He is currently an associate director of CPS Capital Group and Non-Executive Director of European Lithium Ltd.
    Mr Matthew John Hudson Non-Executive Director Mar 2023
    Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
    Mr Sean Michael Hall Chief Executive OfficerManaging Director Apr 2014
    Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
    Mr Kerem Kaya Chief Financial OfficerCompany Secretary May 2021
    Kerem Kaya Chief Financial OfficerCompany Secretary
    Ian Curtinsmith Chief Information Officer
    Luis Vitetta Director of Medical Research
    David Rutolo Director of Science

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Sean Michael Hall 386,838 16.94%
    Farjoy Pty Ltd 205,663 9.01%
    HSBC Custody Nominees (Australia) Limited 106,111 4.65%
    UBS Nominees Pty Ltd 85,316 3.74%
    Fit Investments Pty Ltd <Hallab Investment A/C> 75,563 3.31%
    BNP Paribas Nominees Pty Ltd 73,787 3.23%
    Realm Group Pty Ltd 70,000 3.07%
    Richard Albarran <Albarran Family No 2 A/C> 37,038 1.62%
    Rolay Pty Ltd 37,038 1.62%
    United Trolley Collections P/L 32,970 1.44%
    Mr Michael Jack Hall + Mrs Elizabeth Ann Jones <Hall Jones Super Fund A/C> 29,820 1.31%
    Citicorp Nominees Pty Limited 21,193 0.93%
    Villamagna Inc 20,000 0.88%
    Netwealth Investments Limited 18,839 0.83%
    Acron Holdings Pty Limited <Acron Super Fund A/C> 16,181 0.71%
    Assumo (Nominees) Pty Ltd <Assumo Super Fund A/C> 13,334 0.58%
    D J Fairfull Pty Ltd <Fairfull Super Fund A/C> 12,651 0.55%
    Miss Xiaodan Fu 11,902 0.52%
    Deni Freighters Super Fund Pty Ltd <Deniliquin Freighters Super Fund A/C> 10,001 0.44%
    Daniel P Moses (Nominees) Pty Ltd <Daniel Moses Family A/C> 10,000 0.44%